Compare TNON & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | XRTX |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 3.9M |
| IPO Year | 2021 | 2018 |
| Metric | TNON | XRTX |
|---|---|---|
| Price | $0.91 | $0.84 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 95.4K | ★ 140.0K |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,944,000.00 | N/A |
| Revenue This Year | $44.38 | N/A |
| Revenue Next Year | $39.49 | $392.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.35 | N/A |
| 52 Week Low | $0.96 | $0.35 |
| 52 Week High | $40.95 | $3.60 |
| Indicator | TNON | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 22.15 | 34.58 |
| Support Level | N/A | $0.36 |
| Resistance Level | $4.18 | $2.23 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 4.65 | 0.00 |
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.